| 摘要 |
<p>A 3,7-dithiaprostanoic acid derivative of the formula (I) <CHEM> (wherein, R<1> is OH, C1 SIMILAR 6 alkyloxy, NR<6>R<7> (R<6>, R<7> are H, C1 SIMILAR 6 alkyl.); R<2> is H, OH; R<3> is single bond, C1 SIMILAR 6 alkylene; R<4> is (i) C1 SIMILAR 8 alkyl substituted by C1 SIMILAR 6 alkyloxy, halogen etc., (ii) phenyloxy, C3 SIMILAR 7 cycloalkyloxy, (iii) furyl, furyloxy, thienyl, thienyloxy, naphthyl, naphthyloxy, phthalanyl, phthalanyloxy, (iv) phenyl, phenyloxy, C3 SIMILAR 7 cycloalkyl, C3 SIMILAR 7 cycloalkyloxy substituted by C1 SIMILAR 6 alkyl etc., (v) furyl, furyloxy, thienyl, thienyloxy, naphthyl, naphthyloxy, phthalanyl, phthalanyloxy substituted by C1 SIMILAR 6 alkyl etc.; R<5> is H, C1 SIMILAR 6 alkyl.) can bind PGE2 receptor (particularly, EP4 subtype receptor) strongly. So, they are useful for the prevention and/or treatment of immunological diseases (autoimmune diseases, rejection after organ transplantation etc.), asthma, abnormal bone formation, neuronal cell death, liver damage, nephritis, hypertension, myocardiac ischemia and sleeping disorder etc.</p> |
